GlassScriptPhysician profile
Randy C Gardell
NPI 1659483873
$27,649.19
in general payments reported to CMS, 2019-2025
69 companies · $4,892 in 2025
The $4,892 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,812 · 2020: $3,275 · 2021: $3,835 · 2022: $4,252 · 2023: $4,104 · 2024: $4,480 · 2025: $4,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,419.91 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,856.73 | 2019-2025 | Mavenclad |
| Abbvie INC. | $2,758.24 | 2019-2025 | |
| Biogen, INC. | $1,840.59 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $1,586.38 | 2019-2024 | Austedo, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $1,466.49 | 2019-2025 | |
| Pfizer INC. | $1,005.67 | 2019-2025 | |
| Ucb, INC. | $924.06 | 2019-2025 | Rystiggo, Briviact |
| Supernus Pharmaceuticals, INC. | $820.09 | 2019-2025 | Qelbree |
| Sk Life Science, INC. | $811.74 | 2020-2025 | Xcopri |
| Lundbeck LLC | $778.64 | 2022-2025 | Rexulti, Vyepti |
| Sunovion Pharmaceuticals INC. | $775.38 | 2019-2022 | |
| Allergan, INC. | $775.12 | 2019-2022 | |
| Argenx US, INC. | $773.75 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $761.31 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Acadia Pharmaceuticals INC | $627.89 | 2019-2025 | Nuplazid |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $593.04 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $574.42 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $537.08 | 2024-2025 | Rexulti, Nuedexta |
| Amgen INC. | $520.81 | 2019-2025 | Uplizna, Aimovig |
| Neurocrine Biosciences, INC. | $490.59 | 2019-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $392.37 | 2019-2024 | Rytary, Ongentys 50mg Capsules 30, Ongentys |
| Mallinckrodt Hospital Products INC. | $388.32 | 2020-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $356.94 | 2019-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $344.30 | 2022 | |
| Eisai INC. | $343.91 | 2023-2025 | |
| Tg Therapeutics, INC. | $341.79 | 2024-2025 | |
| Kyowa Kirin, INC. | $304.13 | 2020-2023 | Nourianz |
| Csl Behring | $290.86 | 2019-2025 | Hizentra |
| Acorda Therapeutics, INC | $223.13 | 2019-2023 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $218.34 | 2024-2025 | Hyqvia |
| Mdd US Operations, LLC | $218.09 | 2019-2025 | Gocovri, Gocovri |
| Adamas Pharmaceuticals, INC. | $215.80 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $213.01 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $210.29 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $194.09 | 2020-2021 | |
| Octapharma USA, INC. | $188.19 | 2022-2025 | Panzyga |
| Vanda Pharmaceuticals INC. | $171.00 | 2024-2025 | Ponvory |
| Cycle Pharmaceuticals INC | $159.46 | 2024-2025 | Tascenso Odt, Bafiertam |
| Alnylam Pharmaceuticals INC. | $116.14 | 2022-2024 | Onpattro |
| Arbor Pharmaceuticals, INC. | $115.91 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $111.49 | 2019 | |
| Sumitomo Pharma America, INC. | $104.05 | 2023-2024 | Aptiom |
| Ge Healthcare | $103.40 | 2020-2025 | |
| Corium, LLC | $102.65 | 2023 | Adlarity |
| Promius Pharma LLC | $99.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.94 | 2022 | |
| Avion Pharmaceuticals | $69.40 | 2021-2022 | |
| Tanabe Pharma America, INC. | $57.16 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $52.67 | 2022 | |
| Avanir Pharmaceuticals, INC. | $51.88 | 2019 | |
| Hospira, INC. | $47.18 | 2024 | |
| Neurelis, INC. | $46.73 | 2021 | |
| Assertio Therapeutics, INC. | $43.31 | 2019-2020 | |
| Averitas Pharma INC. | $43.21 | 2023 | Qutenza |
| Xeris Pharmaceuticals, INC. | $40.44 | 2021 | |
| Vertical Pharmaceuticals, LLC | $39.97 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $39.63 | 2020-2024 | |
| Grifols USA, LLC | $37.43 | 2020-2024 | Gamunex-C |
| Springworks Therapeutics, INC. | $24.60 | 2025 | Gomekli |
| Globus Medical, INC. | $23.07 | 2025 | Senza |
| Abbott Laboratories | $19.59 | 2025 | Eterna |
| Ani Pharmaceuticals, INC. | $17.01 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $16.59 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $15.96 | 2023 | |
| Alfasigma USA, INC. | $15.84 | 2021 | |
| Tactile Systems Technology INC | $15.09 | 2024 | Flexitouch Plus, Entre Plus |
| Grt US Holding, INC. | $14.65 | 2022 | |
| Tersera Therapeutics LLC | $12.46 | 2019 | |
| Life Molecular Imaging LTD | $8.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Gardell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.